Health Care & Life Sciences » Pharmaceuticals | Chugai Pharmaceutical Co. Ltd.

Chugai Pharmaceutical Co. Ltd. | Income Statement

Fiscal year is January-December. All values JPY Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
423,652
461,109
498,839
491,780
534,199
579,787
Cost of Goods Sold (COGS) incl. D&A
186,834
217,030
240,316
248,227
254,625
263,762
Gross Income
236,818
244,079
258,523
243,553
279,574
316,025
SG&A Expense
157,867
166,345
169,685
164,233
176,601
186,800
EBIT
80,435
77,734
88,838
79,320
102,973
129,225
Unusual Expense
1,860
1,380
1,269
6,804
6,248
8,544
Non Operating Income/Expense
5,583
389
366
1,986
275
742
Interest Expense
11
6
75
77
61
58
Pretax Income
76,944
76,164
87,276
74,448
97,031
121,449
Income Tax
25,058
24,087
24,923
20,076
23,490
28,370
Consolidated Net Income
51,886
52,077
62,353
54,372
73,541
93,079
Net Income
50,895
50,980
61,125
53,592
72,714
92,488
Net Income After Extraordinaries
50,895
50,980
61,125
53,592
72,714
92,488
Net Income Available to Common
50,895
50,980
61,125
53,592
72,713
92,488
EPS (Basic)
93.47
93.53
112.00
98.12
133.04
169.07
Basic Shares Outstanding
545
545
546
546
547
547
EPS (Diluted)
93.35
93.38
111.79
97.97
132.83
168.80
Diluted Shares Outstanding
545
546
547
547
547
548
EBITDA
94,925
92,614
104,405
95,689
119,307
145,803
Other Operating Expense
1,484
-
-
-
-
-
Non-Operating Interest Income
243
205
148
81
93
83
Minority Interest Expense
991
1,097
1,228
780
827
591

About Chugai Pharmaceutical Co.

View Profile
Address
Nihonbashi Mitsui Tower, 15/F
Tokyo Tokyo 103
Japan
Employees -
Website http://www.chugai-pharm.co.jp
Updated 07/08/2019
Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of the pharmaceuticals. Its operations are carried out through the following business divisions: Research, Development, Production, Marketing, Medical Affairs and Drug Safety. The Research division focuses its efforts on creating innovative drugs by using its competitive strengths that include proprietary antibody technologies and cutting-edge research resources.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.